drugset
Drugs / Oprozomib
last change Oct 2022 re-read 9 days ago

Oprozomib

also known as ONX 0912 · Pr-047

Small molecule

Developed for
plasma cell myeloma · cancer · hepatocellular carcinoma · refractory plasma cell neoplasm · Waldenstrom macroglobulinemia
Investigated by
Amgen

Trials 9

today NCT02939183 · Ph 1 NCT02227914 · Ph 1/2 NCT02244112 · Ph 1 NCT01999335 · Ph 1 NCT02072863 · Ph 1/2 NCT01881789 · Ph 1/2 NCT01832727 · Ph 1/2 NCT01416428 · Ph 1/2 NCT01129349 · Ph 1
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT02939183 Jan 2017 → Oct 2022 refractory plasma cell neoplasm Amgen Completed No outcome recorded
Phase 1 NCT02244112 Aug 2014 → May 2015 — Amgen Terminated No outcome recorded Stop: Enrollment
Phase 1 NCT01999335 Jul 2014 → Apr 2019 plasma cell myeloma Amgen Terminated No outcome recorded Stop: Enrollment
Phase 1 NCT01129349 Apr 2010 → Nov 2012 cancer Amgen Completed No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT02227914 Dec 2014 → Mar 2015 hepatocellular carcinoma Amgen Withdrawn No outcome recorded
Phase 1/2 NCT02072863 Jan 2014 → Jan 2015 plasma cell myeloma Amgen Completed No outcome recorded
Phase 1/2 NCT01881789 Oct 2013 → Sep 2019 plasma cell myeloma Amgen Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT01832727 Jul 2013 → Jun 2019 plasma cell myeloma Amgen Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT01416428 Oct 2011 → Aug 2016 Waldenstrom macroglobulinemia, plasma cell myeloma Amgen Terminated No outcome recorded Stop: Enrollment

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as Oprozomib “(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects...” NCT02939183 ↗
8

NCT01416428 ↗

NCT01832727 ↗

NCT02227914 ↗

NCT02244112 ↗

NCT01999335 ↗

NCT02072863 ↗

NCT01881789 ↗

NCT01129349 ↗
Known as ONX 0912 ChEMBL registry synonym — accepted as the source's own label CHEMBL2103884 ↗
Known as Pr-047 ChEMBL registry synonym — accepted as the source's own label CHEMBL2103884 ↗
Action Inhibit “Oprozomib is an oral proteasome inhibitor with activity in multiple myeloma (MM).” PMID 31229804 ↗ Jun 2019
Modality Small molecule — CHEMBL2103884 ↗
Route Oral “Oral administration of Oprozomib on Days 1-5 of a 14 day cycle” NCT01129349 ↗